A MULTICENTER, PROSPECTIVE, RANDOMIZED, OPEN LABEL, BLINDED-ENDPOINT, CONTROLLED, SINGLE-DOSE TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF NONO-42 IN PARTICIPANTS WITH ACUTE ISCHEMIC STROKE SELECTED FOR THROMBOLYSIS WITH OR WITHOUT ENDOVASCULAR THROMBECTOMY (ACT-42 TRIAL)
- Registry ID
- NONO42-02
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- NONO INC
- Start date
- 2025-07-18
- Last update
- 2023-09-21
Conditions
Related clinical trials
- Prospective Evaluation of Atrial Fibrillation-Related Stroke Patients in Rehabilitation Program (PEARL), an Observational Cohort Study
- THROMBOLYSIS DOMAIN (ACT WHEN) A MULTI-FACTORIAL, MULTI-ARM, MULTI-STAGE, RANDOMISED,
GLOBAL ADAPTIVE PLATFORM TRIAL FOR STROKE (ACT-GLOBAL)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND SAFETY OF MILVEXIAN, AN ORAL FACTOR XIA INHIBITOR, FOR STROKE PREVENTION AFTER AN ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK
- REEXAMINING HER CARDIOVASCULAR RISK - OTTAWA WOMEN'S LONGITUDINAL COHORT STUDY (HER CROWN)
- THE CANADIAN MARAVIROC RANDOMIZED CONTROLLED TRIAL TO AUGMENT REHABILITATION OUTCOMES AFTER STROKE (CAMAROS)
- RFVIIA FOR ACUTE HEMORRHAGIC STROKE ADMINISTERED AT EARLIEST TIME (FASTEST)
View on source registry